bioMérieux, a world leader in the field of in vitro diagnostics, will unveil a new suite of “Full Microbiology Laboratory Automation” solutions at the 108th General Meeting of the American Society for Microbiology (ASM), held June 1-5 in Boston. bioMérieux believes that full microbiology laboratory automation is imperative to streamlining operations and making more reliable results available faster, particularly in light of the growing threat of healthcare-associated infections. Enhanced automation offsets an increasing lack of specialized personnel, contributing to the control of healthcare expenditures.
Schweiz
bioMérieux and FIND to Collaborate on Infectious Disease Diagnostics
15 Mai, 2008
bioMérieux, a leader in the field of in vitro diagnostics and FIND (the Foundation for Innovative New Diagnostics), a Swiss non-profit foundation, have signed a Memorandum of Understanding to jointly undertake development projects in the field of infectious disease diagnostics.
University of Sunderland and bioMérieux Collaborate in New Research Significantly Improving the Identification of Pseudomonas aeruginosa. A Major Cause of Death in Cystic Fibrosis Patients
03 April, 2008
A team of researchers from the University of Sunderland and bioMérieux, a leading company in the field of in vitro diagnostics, have achieved a new step in the fight against Pseudomonas aeruginosa, a bacterium responsible for deadly healthcare-associated infections, which kills tens of thousands of people throughout the world every year .1
FDA Clears bioMérieux’s VIDAS® NT-proBNPA High Medical Value Test for Diagnosis of Heart Failure
13 März, 2008
bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® NT-proBNP, a test that helps the diagnosis of heart failure.
bioMérieux’s Food Safety Handbook is Now Available
26 Februar, 2008
bioMérieux participates in a project on Legionella and legionellosis
20 Februar, 2008